Search results for: Pricing and Reimbursement
Filter search results
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
…Thailand’s HTA agency, the Health Intervention and Technology Assessment Program (HITAP), and HTA has since become a requirement before making reimbursement decisions for the UCS. The other two schemes, CSMBS and SSS,…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…be low. Benefits and weaknesses of TEVs and of the European Commission’s proposals The TEV proposal has been controversial and we set out the arguments for and against drawing on…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…In reality, indication launches within a country can be costly, with significant investment needed in regulatory and HTA submission and compliance, manufacturing and distribution adjustments, marketing and commercialisation, and any…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…development of combination therapies becoming more common in oncology and beyond, and a lack of agreed-upon pricing models in Europe, the need for innovative pricing strategies is increasingly evident. The…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…Pricing and Reimbursement The OHE team addressed various aspects of pricing and reimbursement (P&R) during the last quarter of 2011. At the ISPOR Europe meeting in November, Adrian Towse and…
A Spotlight on Haemophilia Therapies
3 October 2024
…bodies must foster a supportive policy environment that recognises and rewards innovation, including intellectual property protection, transparent approval requirements and processes, and pricing and reimbursement policies that incentivise and reward…
Update: Value-Based Pricing in the UK
11 January 2011
…replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post. Since the late 1950s, prices for medicines in…
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
…facilitation of market access, and capacity and funding support. Making the process – and the resulting HTA reports- evidence-based and public once they are reviewed and finalized will be vital,…